Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2.45 CAD | -1.61% | +3.38% | +483.33% |
May. 22 | Medicenna to Present Clinical Update on MDNA11 ABILITY-1 Trial at Sachs Oncology Innovation Forum | MT |
May. 13 | Medicenna Says ABILITY-1 Abstract Withdrawn by ASCO Program Committee | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+483.33% | 136M | |
+62.95% | 62.59B | |
-2.46% | 41.18B | |
+44.53% | 40.29B | |
-8.29% | 27.9B | |
+12.56% | 26.21B | |
-21.78% | 19.09B | |
+5.19% | 13.08B | |
+24.68% | 12.26B | |
+28.19% | 12.05B |
- Stock Market
- Equities
- MDNA Stock
- News Medicenna Therapeutics Corp.
- Medicenna Brief: Net loss for the quarter ended December 31, 2023, was $5.0 million or ($0.07) per share compared to a net loss of $1.1 million or ($0.02) per share for the quarter ended December 31, 2022